Results 11 to 20 of about 117 (84)
Human Vaccines & Immunotherapeutics, 2019 Dengue is prevalent in the Asia-Pacific region. Participants of two immunogenicity and safety phase II studies conducted in Singapore and Vietnam (NCT0088089 and NCT00875524, respectively) were followed for up to four years after third vaccine dose of a ...
Ngoc Huu Tran +10 more
doaj +2 more sources
Advancing dengue vaccine development: Challenges, innovations, and the path toward global protection
Pediatric InvestigationDengue fever remains a significant global health threat, placing nearly half of the world's population at risk. Despite decades of research, developing an effective dengue vaccine continues to face multiple challenges, including antibody‐dependent ...
Ran Wang +3 more
doaj +2 more sources
Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning
Nature Communications, 2018 Clinical trials for the CYD-TDV dengue vaccine showed that vaccine efficacy varies with prior dengue exposure, but baseline serostatus is only known for 12% of subjects. Here, Dorigatti et al.
I. Dorigatti +6 more
doaj +2 more sources
A Maximum Entropy Model of the Distribution of Dengue Serotype in Mexico
Transboundary and Emerging Diseases, Volume 2023, Issue 1, 2023., 2023 Pathogen strain diversity is an important driver of the trajectory of epidemics. The role of bioclimatic factors on the spatial distribution of dengue virus (DENV) serotypes has, however, not been previously studied. Hence, we developed municipality‐scale environmental suitability maps for the four dengue virus serotypes using maximum entropy modeling.
Esther Annan +11 more
wiley +1 more source
Suppression of TGF‐β/Smad2 signaling by GW788388 enhances DENV‐2 clearance in macrophages
Journal of Medical Virology, Volume 94, Issue 9, Page 4359-4368, September 2022., 2022 Abstract Dengue fever, caused by the dengue virus (DENV‐1, −2, −3, and −4), affects millions of people in the tropical and subtropical regions worldwide. Severe dengue is correlated with high viraemia and cytokine storm, such as high levels of transforming growth factor‐β1 (TGF‐β1) in the patient's serum.
Gabrielly Sbano Teixeira +7 more
wiley +1 more source
Pharmacoepidemiology and Drug Safety, Volume 31, Issue 7, Page 758-768, July 2022., 2022 Abstract Purpose We evaluated the effectiveness of additional risk minimisation measures (aRMMs; i.e., educational materials) distributed to prescribers to ensure that only individuals with evidence of prior dengue infection (PDI, i.e., dengue seropositive) would be vaccinated with the tetravalent dengue vaccine (CYD‐TDV; Dengvaxia®).
Mariana F. Almas +4 more
wiley +1 more source
MedComm, Volume 3, Issue 2, June 2022., 2022 Live‐attenuated vaccine SA14‐14‐2 and chimeric vaccine JE‐CV are two kinds of JEV vaccines available worldwide. The satisfied immune protection relays humoral and cellular immunity. The nonstructural proteins of SA14‐14‐2 can elicit robust T‐cell response, but JE‐CV lack the nonstructural proteins of JEV.
Enyue Fang +8 more
wiley +1 more source
Journal of Tropical Medicine, Volume 2022, Issue 1, 2022., 2022 Dengue is a Flavivirus infection transmitted through mosquitoes of the Aedes genus, which is known to occur in over 100 countries of the world. Dengue has no available drugs for treatment; CYD‐TDV is the only vaccine thus far approved for use by a few countries in the world.
Partha Biswas +13 more
wiley +1 more source
Plant Biotechnology Journal, Volume 19, Issue 4, Page 745-756, April 2021., 2021 Summary Dengue virus (DENV) is an emerging threat causing an estimated 390 million infections per year. Dengvaxia, the only licensed vaccine, may not be adequately safe in young and seronegative patients; hence, development of a safer, more effective vaccine is of great public health interest.
Daniel Ponndorf +10 more
wiley +1 more source
BioMed Research International, Volume 2021, Issue 1, 2021., 2021 Dengue remains one of the most serious and widespread mosquito‐borne viral infections in human beings, with serious health problems or even death. About 50 to 100 million people are newly infected annually, with almost 2.5 billion people living at risk and resulting in 20,000 deaths.
Muhammad Torequl Islam +16 more
wiley +1 more source